Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. The Alpha CaRT technology of the company utilizes the therapeutic properties of alpha particles aiming to overcome, and harness for benefit for alpha radiation's range. The company derives maximum revenue from Israel.
Founded: | 2015 | Country: | Israel |
Employees: | N/A | City: | N/A |
Market Cap: | 159.1M | IPO Year: | N/A |
Target Price: | $8.00 | AVG Volume (30 days): | 65.2K |
Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.42 | EPS Growth: | N/A |
52 Week Low/High: | $1.75 - $3.40 | Next Earning Date: | 11-19-2024 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
DRTS Breaking Stock News: Dive into DRTS Ticker-Specific Updates for Smart Investing
GlobeNewswire
6 days ago
GlobeNewswire
7 days ago
GlobeNewswire
13 days ago
GlobeNewswire
18 days ago
Simply Wall St.
23 days ago
GlobeNewswire
a month ago
GlobeNewswire
a month ago
Simply Wall St.
2 months ago
The information presented on this page, "DRTS Alpha Tau Medical Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.